Time-restricted eating is sold as a fatty liver fix. Five trials show a partial effect.
Pooling 291 participants, researchers found time-restricted eating modestly lowered a liver enzyme and body mass index — but didn't significantly reduce liver fat itself or improve insulin resistance.
Time-restricted eating — confining food intake to a set daily window rather than changing what's eaten — has become one of the most widely adopted diet trends of the past several years, often promoted as a way to improve liver and metabolic health. A meta-analysis published this summer tested that claim specifically in people with metabolic dysfunction-associated steatotic liver disease, or MASLD, the condition previously known as non-alcoholic fatty liver disease [s1].
What the analysis pooled
Researchers systematically searched PubMed, Ovid, Web of Science, and clinical trial registries for randomized controlled trials, with searches conducted through December 2025 [s1]. Eligible studies had to enroll non-diabetic adults with MASLD — defined as hepatic steatosis, or fat buildup in the liver, exceeding 5% — who underwent time-restricted eating for at least four weeks [s1]. Five trials, together covering 291 participants across China and Iran, met the inclusion criteria [s1]. The researchers used random-effects models to pool results and graded the certainty of the overall evidence using the standard GRADE framework [s1].
Where a real, if modest, effect showed up
Time-restricted eating produced a statistically significant reduction in serum alanine aminotransferase, or ALT, a liver enzyme commonly used as a marker of liver inflammation or damage, compared with non-restricted eating (mean difference of -7.28, 95% CI -12.27 to -2.29, p = 0.004) [s1]. Among the secondary outcomes tracked, only body mass index showed a significant, if small, improvement (mean difference of -0.87 kg/m², 95% CI -1.57 to -0.18, p = 0.01) [s1].
Where the evidence didn't support a benefit
On the outcomes most directly tied to the disease itself, the picture was less encouraging. The analysis found no significant difference in liver fat content — the core marker of the disease MASLD is actually named for — nor in AST, a second liver enzyme, nor in HOMA-IR, a standard measure of insulin resistance [s1]. Lipid levels, fasting glucose, and inflammatory markers also showed no consistent benefit from time-restricted eating across the pooled trials [s1].
Why the certainty rating matters here
Beyond the specific numbers, the review's authors rate the overall certainty of evidence as ranging from very low to low [s1] — the weakest tier on the standard GRADE scale, reflecting substantial clinical and methodological heterogeneity across the five trials, plus the small overall sample size and short intervention durations typical of the available research [s1]. A "very low to low" certainty rating means genuine confidence in these findings, in either direction, should be limited — not just for the outcomes with no significant effect, but for the ALT and BMI findings that did reach statistical significance too.
What this means for someone considering time-restricted eating for liver health
The honest summary sits between the trend's marketing and outright dismissal: this pooled analysis found time-restricted eating modestly improved one liver enzyme and body weight in people with MASLD, but did not significantly move liver fat content itself — the actual disease marker — or insulin resistance, the metabolic dysfunction underlying the condition [s1]. The researchers' own conclusion is that TRE yields modest improvements in some markers but does not significantly improve hepatic steatosis or core metabolic indices in this population [s1], and they call explicitly for larger randomized trials with standardized protocols and longer follow-up before the intervention's actual clinical efficacy for this condition can be established [s1].
Sources
Sources
More on
Weight loss modifies some diseases and is untested in most of the ones it is blamed for
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
A glucagon-GLP-1 dual agonist cleared its liver-fat endpoint in a 216-person phase 3
SYNCHRONIZE-MASLD reports 84.2% of survodutide patients hitting a 30% cut in liver fat at 48 weeks. The trial measured fat on MRI, not fibrosis on biopsy — which is where the harder question still sits.
Egypt cured millions of hepatitis C. Its liver cancer problem did not go away
Two 2026 reviews describe the same handover: as the virus recedes, obesity-driven fatty liver disease is moving into the space it occupied — in a population where roughly 40% of screened adults met obesity criteria.
Does stevia mess with your blood sugar or hormones? A crossover trial says no
In 69 people across normal weight, overweight and type 2 diabetes, a stevia drink behaved like water — no shift in glucose, insulin, gut hormones, appetite or how much they ate next.